CommercialCoverageMedium impact
06.02.56i, Noninvasive Techniques for the Evaluation and Monitoring of Individuals with Chronic Liver Disease
Independence Blue Cross·Gastroenterology, Internal Medicine·Medical Policy
Effective date
Jun 24, 2026
We identified it
Jun 25, 2026
Summary
Policy 06.02.56i regarding noninvasive techniques for evaluation and monitoring of chronic liver disease has been reissued effective 06/24/2026. The billing team must obtain and review the full policy text to identify specific changes to coverage, billing codes, prior authorization requirements, or documentation standards that may affect claims processing for hepatology and gastroenterology services.
Action Required
By 06/24/2026: Billing team must access the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-06-02-56i to review specific coverage criteria, applicable CPT/HCPCS codes, prior authorization triggers, and documentation requirements for noninvasive liver disease evaluation procedures (such as ultrasound elastography, FibroScan, serum biomarkers, and imaging studies). Update billing system rules, prior authorization workflows, and provider encounter forms accordingly. Notify providers and gastroenterology/hepatology staff of any changes to ensure compliant coding and documentation. Failure to implement required changes may result in claim denials for liver disease monitoring procedures.